PUBLISHER: Grand View Research | PRODUCT CODE: 1587515
PUBLISHER: Grand View Research | PRODUCT CODE: 1587515
The global tangential flow filtration market size is expected to reach USD 4.13 billion by 2030, registering to grow at a CAGR of 12.4% from 2025 to 2030 according to a new report by Grand View Research, Inc. The major factors contributing to the market growth are the advantages offered by tangential flow filtration (TFF) over normal flow filtration, the increasing demand for vaccines and therapeutics derived from bioprocessing operations, and the rising investments for exhaustive R&D activities to develop new technologies in TFF.
The use of TFF technology increased during the COVID-19 pandemic as the separation process was widely employed during the vaccine manufacturing process. TFF products observed an increased adoption during COVID-19 research for the development and manufacturing of vaccines as treatment plans. The pandemic also witnessed an increase in the usage of single-use bioprocessing systems, which further fueled the market expansion. In addition, several initiatives by the governments and key manufacturers were introduced to boost the vaccine development for curbing the spread of SARS-CoV-2 infection. For instance, in April 2021, Meissner Filtration Products, Inc. announced that it has secured a contract of USD 13.4 million from the U.S. government, BARDA (Biomedical Advanced Research and Development Authority) to expand its capacity and produce single-use systems to support the manufacturing of vaccines for COVID-19. Thereby, the increased production of vaccines has positively impacted the TFF product demand and fueled its growth.
TFF or sometimes referred to as cross-flow filtration is a technique used for the separation and purification of molecules, wherein the feed solution flows in a parallel direction to the membrane filter. During this process, some of the flow streams pass through the filter while the rest is concentrated by recirculation in the system. The TFF technology is utilized across both upstream and downstream processes due to its numerous advantages such as low running costs, enhanced control and efficiency, reduced cross-contamination, easy scale-up or down, and increased shelf life. These advantages have allowed TFF application in a range of fields such as biochemistry, molecular biology, and immunology. Additionally, the increasing demand for biopharmaceuticals due to lesser side effects, personalized treatments, and novel therapies has resulted in the expansion of manufacturing capabilities. CMOs and CROs also witnessed a rise in the manufacturing of vaccines and therapeutics due to the upswing in the demand for commercial biopharmaceuticals. For instance, in June 2022, Merck KGaA announced expanding its existing CDMO facility in Wisconsin, USA. This new expansion project of USD 58 million (EUR 59 million) is targeted to increase the production of highly potent active pharmaceutical ingredients for meeting the growing demand for therapies for critical cancer. The rise in the manufacturing of and demand for biopharmaceuticals attributes to the adoption of TFF products across harvesting, separation, and purification processes, therefore propelling the growth of the marketplace.